Leerink Partnrs Reduces Earnings Estimates for ICON Public

ICON Public Limited (NASDAQ:ICLR - Free Report) - Investment analysts at Leerink Partnrs lowered their FY2025 EPS estimates for ICON Public in a note issued to investors on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $14.11 per share for the year, down from their prior forecast of $14.58. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for ICON Public's current full-year earnings is $13.42 per share. Leerink Partnrs also issued estimates for ICON Public's FY2026 earnings at $15.94 EPS and FY2027 earnings at $17.95 EPS.

ICON Public (NASDAQ:ICLR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analysts' expectations of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.10 EPS.

A number of other equities research analysts have also issued reports on the stock. Evercore ISI reduced their target price on shares of ICON Public from $360.00 to $350.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. Robert W. Baird reduced their price target on shares of ICON Public from $249.00 to $225.00 and set a "neutral" rating for the company in a research report on Wednesday. Barclays lowered their price target on ICON Public from $330.00 to $275.00 and set an "overweight" rating on the stock in a report on Friday, October 25th. Redburn Atlantic assumed coverage on ICON Public in a research note on Monday, October 14th. They issued a "neutral" rating and a $311.00 price target on the stock. Finally, StockNews.com cut ICON Public from a "buy" rating to a "hold" rating in a research report on Thursday, September 19th. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $292.45.

ICON Public Stock Performance

NASDAQ ICLR opened at $203.67 on Thursday. The stock has a fifty day simple moving average of $261.38 and a 200-day simple moving average of $299.05. The stock has a market cap of $16.80 billion, a PE ratio of 22.71, a P/E/G ratio of 1.45 and a beta of 1.25. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35.

Institutional Investors Weigh In On ICON Public

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Foyston Gordon & Payne Inc acquired a new stake in ICON Public during the third quarter valued at approximately $11,672,000. Icon Wealth Advisors LLC raised its position in shares of ICON Public by 861.1% during the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company's stock worth $3,797,000 after purchasing an additional 11,840 shares during the period. First Horizon Advisors Inc. increased its position in ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company's stock worth $172,000 after buying an additional 151 shares during the period. Arkadios Wealth Advisors boosted its holdings in shares of ICON Public by 5.0% during the third quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company's stock valued at $371,000 after acquiring an additional 62 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. grew its position in shares of ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company's stock worth $147,000 after acquiring an additional 96 shares during the last quarter. Institutional investors own 95.61% of the company's stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.